Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Targeting the cancer mutanome of breast cancer.

Radvanyi LG.

Nat Med. 2018 Jun;24(6):703-704. doi: 10.1038/s41591-018-0065-z. No abstract available.

PMID:
29867234
2.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C.

Clin Cancer Res. 2018 Sep 15;24(18):4416-4428. doi: 10.1158/1078-0432.CCR-17-3649. Epub 2018 May 30.

3.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.

Tavera RJ, Forget MA, Kim YU, Sakellariou-Thompson D, Creasy CA, Bhatta A, Fulbright OJ, Ramachandran R, Thorsen ST, Flores E, Wahl A, Gonzalez AM, Toth C, Wardell S, Mansaray R, Radvanyi LG, Gombos DS, Patel SP, Hwu P, Amaria RN, Bernatchez C, Haymaker C.

J Immunother. 2018 Nov/Dec;41(9):399-405. doi: 10.1097/CJI.0000000000000230.

PMID:
29757889
4.

Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells.

An X, Sendra VG, Liadi I, Ramesh B, Romain G, Haymaker C, Martinez-Paniagua M, Lu Y, Radvanyi LG, Roysam B, Varadarajan N.

PLoS One. 2017 Aug 24;12(8):e0181904. doi: 10.1371/journal.pone.0181904. eCollection 2017.

5.

Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.

Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C.

Clin Cancer Res. 2017 Oct 15;23(20):6151-6164. doi: 10.1158/1078-0432.CCR-16-1217. Epub 2017 Jul 28.

6.

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.

Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, Overwijk WW, Hwu P, Yi Q, Kwak L, Yang Z, Mak TW, Li W, Radvanyi LG, Ni L, Liu D, Dong C.

Cell Res. 2017 Aug;27(8):1034-1045. doi: 10.1038/cr.2017.90. Epub 2017 Jul 7.

7.

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.

Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM.

Cancer Immunol Res. 2017 Jun;5(6):439-445. doi: 10.1158/2326-6066.CIR-16-0364. Epub 2017 May 4.

8.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.

BMC Med. 2016 Oct 25;14(1):168.

9.

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.

Sim GC, Wu S, Jin L, Hwu P, Radvanyi LG.

Oncotarget. 2016 Jun 14;7(24):36074-36091. doi: 10.18632/oncotarget.8683.

10.

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.

Forget MA, Haymaker C, Dennison JB, Toth C, Maiti S, Fulbright OJ, Cooper LJ, Hwu P, Radvanyi LG, Bernatchez C.

Oncoimmunology. 2015 Jun 5;5(2):e1057386. eCollection 2016 Feb.

11.

Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions.

Radvanyi LG.

Cancer J. 2015 Nov-Dec;21(6):450-64. doi: 10.1097/PPO.0000000000000162. Review.

PMID:
26588676
12.

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.

Haymaker CL, Wu RC, Ritthipichai K, Bernatchez C, Forget MA, Chen JQ, Liu H, Wang E, Marincola F, Hwu P, Radvanyi LG.

Oncoimmunology. 2015 Mar 16;4(8):e1014246. eCollection 2015 Aug.

13.

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.

Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P.

Cancer Immunol Res. 2015 Nov;3(11):1201-6. doi: 10.1158/2326-6066.CIR-15-0071. Epub 2015 Jul 27.

14.

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.

Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizée G.

Cancer Immunol Res. 2015 Jun;3(6):602-9. doi: 10.1158/2326-6066.CIR-15-0030. Epub 2015 Mar 20.

15.

Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.

Harao M, Mittendorf EA, Radvanyi LG.

BioDrugs. 2015 Feb;29(1):15-30. doi: 10.1007/s40259-014-0114-1. Review.

PMID:
25523015
16.

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.

Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, Haymaker C, Bernatchez C, Huls H, Wang E, Marincola FM, Hwu P, Cooper LJ, Radvanyi LG.

J Immunother. 2014 Nov-Dec;37(9):448-60. doi: 10.1097/CJI.0000000000000056.

17.

An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis.

Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM.

Biomark Cancer. 2013 Nov 19;5:71-80. doi: 10.4137/BIC.S13236. eCollection 2013.

18.

Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG.

Oncoimmunology. 2013 Sep 1;2(9):e25581. Epub 2013 Jul 3.

19.

Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer.

Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG.

Ann Oncol. 2013 Oct;24(10):2534-42. doi: 10.1093/annonc/mdt190. Epub 2013 May 31.

20.

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30.

21.

New insights on the role of CD8(+)CD57(+) T-cells in cancer.

Wu RC, Hwu P, Radvanyi LG.

Oncoimmunology. 2012 Sep 1;1(6):954-956.

22.

Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.

Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ.

J Immunol. 2012 Dec 1;189(11):5476-84. doi: 10.4049/jimmunol.1201221. Epub 2012 Oct 26.

23.

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P.

Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.

24.

Advances in the development of cancer immunotherapies.

Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P.

Trends Immunol. 2013 Feb;34(2):90-8. doi: 10.1016/j.it.2012.08.004. Epub 2012 Sep 30. Review.

25.

MUC1 glycopeptide epitopes predicted by computational glycomics.

Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, Xu H, Shi Y, Wang LX, Ross JA, Rodrigues SP, Almeida IC, Yang X, Qu J, Schocker NS, Michael K, Zhou D.

Int J Oncol. 2012 Dec;41(6):1977-84. doi: 10.3892/ijo.2012.1645. Epub 2012 Sep 27.

26.

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.

Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G.

Clin Cancer Res. 2012 Oct 1;18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632. Epub 2012 Jul 31.

27.

Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Bernatchez C, Radvanyi LG, Hwu P.

Semin Oncol. 2012 Apr;39(2):215-26. doi: 10.1053/j.seminoncol.2012.01.006. Review.

28.

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG.

Cancer J. 2012 Mar-Apr;18(2):160-75. doi: 10.1097/PPO.0b013e31824d4465. Review.

29.

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.

Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P.

Clin Cancer Res. 2012 Apr 15;18(8):2326-35. doi: 10.1158/1078-0432.CCR-11-2515. Epub 2012 Feb 21. Erratum in: Clin Cancer Res. 2012 Jul 1;18(13):3715.

30.

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG.

Clin Cancer Res. 2012 May 1;18(9):2465-77. doi: 10.1158/1078-0432.CCR-11-2034. Epub 2012 Feb 3.

31.

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.

Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG.

Clin Cancer Res. 2011 Jul 15;17(14):4882-91. doi: 10.1158/1078-0432.CCR-10-2769. Epub 2011 Jun 1.

32.

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.

J Immunother. 2011 Apr;34(3):236-50. doi: 10.1097/CJI.0b013e318209e7ec.

33.

Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals.

Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ, Radvanyi LG.

Vaccine. 2011 Apr 5;29(16):3021-30. doi: 10.1016/j.vaccine.2011.01.115. Epub 2011 Feb 12.

34.

Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs.

Li D, Li Y, Hernandez JA, Patenia R, Kim TK, Khalili J, Dougherty MC, Hanley PJ, Bollard CM, Komanduri KV, Hwu P, Champlin RE, Radvanyi LG, Molldrem JJ, Ma Q.

J Immunother. 2010 Nov-Dec;33(9):975-82. doi: 10.1097/CJI.0b013e3181fb0486.

35.

2E8 binds to the high affinity I-domain in a metal ion-dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1.

Carreño R, Brown WS, Li D, Hernandez JA, Wang Y, Kim TK, Craft JW Jr, Komanduri KV, Radvanyi LG, Hwu P, Molldrem JJ, Legge GB, McIntyre BW, Ma Q.

J Biol Chem. 2010 Oct 22;285(43):32860-8. doi: 10.1074/jbc.M110.111591. Epub 2010 Aug 19.

36.

Development and application of 'phosphoflow' as a tool for immunomonitoring.

Wu S, Jin L, Vence L, Radvanyi LG.

Expert Rev Vaccines. 2010 Jun;9(6):631-43. doi: 10.1586/erv.10.59. Review.

37.

A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology.

Campbell-Anson RE, Kentor D, Wang YJ, Bushnell KM, Li Y, Vence LM, Radvanyi LG.

J Immune Based Ther Vaccines. 2008 Mar 6;6:1. doi: 10.1186/1476-8518-6-1.

38.

Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.

Lizée G, Radvanyi LG, Overwijk WW, Hwu P.

Clin Cancer Res. 2006 Aug 15;12(16):4794-803. Review.

39.

Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.

Lizée G, Radvanyi LG, Overwijk WW, Hwu P.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2359s-2365s. Review.

40.

A central role for IL-2 in fate determination of mature T cells--I: role in determining the Th1/Th2 profile in primary T cell cultures.

Raju K, Rabinovich BA, Radvanyi LG, Spaner D, Miller RG.

Int Immunol. 2001 Dec;13(12):1453-9.

PMID:
11717186
41.
42.

Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.

LaCasse EC, Bray MR, Patterson B, Lim WM, Perampalam S, Radvanyi LG, Keating A, Stewart AK, Buckstein R, Sandhu JS, Miller N, Banerjee D, Singh D, Belch AR, Pilarski LM, Gariépy J.

Blood. 1999 Oct 15;94(8):2901-10.

PMID:
10515895
43.

Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice.

Radvanyi LG, Raju K, Spaner D, Mills GB, Miller RG.

Cell Immunol. 1998 Jan 10;183(1):1-12.

PMID:
9578714
44.

Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis.

Radvanyi LG, Shi Y, Mills GB, Miller RG.

Cell Immunol. 1996 Jun 15;170(2):260-73.

PMID:
8660826
45.

CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response.

Radvanyi LG, Shi Y, Vaziri H, Sharma A, Dhala R, Mills GB, Miller RG.

J Immunol. 1996 Mar 1;156(5):1788-98.

PMID:
8596028
46.

CD28-mediated signaling in vivo prevents activation-induced apoptosis in the thymus and alters peripheral lymphocyte homeostasis.

Shi Y, Radvanyi LG, Sharma A, Shaw P, Green DR, Miller RG, Mills GB.

J Immunol. 1995 Aug 15;155(4):1829-37.

PMID:
7543534
47.

Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.

Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB.

Cancer Res. 1995 May 1;55(9):1982-8.

48.

Early detection of apoptosis in defined lymphocyte populations in vivo.

Zhang L, Wang C, Radvanyi LG, Miller RG.

J Immunol Methods. 1995 Apr 12;181(1):17-27.

PMID:
7730663
49.
50.

Immobilization of cells by spontaneous adhesio.

Facchini PJ, Dicosmo F, Radvanyi LG, Neumann AW.

Methods Mol Biol. 1990;6:513-23. doi: 10.1385/0-89603-161-6:513.

PMID:
21390633

Supplemental Content

Loading ...
Support Center